Research > Focus C > Work Packages C01
This project aims to comprehensively assess the tumor exposure of drugs & biologicals commonly used for the treatment of adult and pediatric glioblastoma in order to preclinically prioritize and de-prioritize drugs & biologicals (and combinations thereof) based on their pharmacological properties and thus suitability for the treatment of patients with brain tumors. We will utilize a large spectrum of methodologies and the UNITE Core Collection of orthotopic preclinical models of different molecular subgroups of glioblastoma (genetic mouse models with an intact immune system and patient-derived xenograft models transplanted into immunodeficient mice). This information will be integrated with molecular information including immune microenvironment, the transportome, imaging information, and response evaluation in the same models. The visual abstract below shows the aims and planned tasks of the work package.